Serious adverse events associated with yellow fever vaccine
Open Access
- 4 June 2015
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 11 (9) , 2183-2187
Abstract
Yellow fever vaccine was considered one of the safest vaccines, but in recent years it was found that it could rarely cause invasive and disseminated disease in some otherwise healthy individuals, with high lethality. After extensive studies, although some risk factors have been identified, the real cause of causes of this serious adverse event are largely unknown, but findings point to individual host factors. Meningoencephalitis, once considered to happen only in children less than 6 months of age, has also been identified in older children and adults, but with good prognosis. Efforts are being made to develop a safer yellow fever vaccine, and an inactivated vaccine or a vaccine prepared with the vaccine virus envelope produced in plants are being tested. Even with serious and rare adverse events, yellow fever vaccine is the best way to avoid yellow fever, a disease of high lethality and should be used routinely in endemic areas, and on people from non-endemic areas that could be exposed, according to a careful risk-benefit analysis.Keywords
This publication has 44 references indexed in Scilit:
- Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in MaliTransactions of the Royal Society of Tropical Medicine and Hygiene, 2012
- The Safety of Yellow Fever Vaccine 17D or 17DD in Children, Pregnant Women, HIV+ Individuals, and Older Persons: Systematic ReviewThe American Journal of Tropical Medicine and Hygiene, 2012
- Elderly Subjects Have a Delayed Antibody Response and Prolonged Viraemia following Yellow Fever Vaccination: A Prospective Controlled Cohort StudyPLOS ONE, 2011
- Yellow Fever Virus Vaccine–associated Deaths in Young Women1Emerging Infectious Diseases, 2011
- Persistence of yellow fever vaccine RNA in urineVaccine, 2011
- Detection of Yellow Fever 17D Genome in UrineJournal of Clinical Microbiology, 2011
- Clinical and Immunological Insights on Severe, Adverse Neurotropic and Viscerotropic Disease following 17D Yellow Fever VaccinationClinical and Vaccine Immunology, 2010
- Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIV‐Infected PatientsClinical Infectious Diseases, 2009
- Anamnestic immune response to dengue and decreased severity of yellow feverJournal of Global Infectious Diseases, 2009
- Case of Yellow Fever Vaccine–Associated Viscerotropic Disease with Prolonged Viremia, Robust Adaptive Immune Responses, and Polymorphisms in CCR5 and RANTES GenesThe Journal of Infectious Diseases, 2008